Eden Biodesign and iQur to Develop Vaccine for Hepatitis A and B
Eden Biodesign Ltd. (Liverpool, UK) and iQur Ltd. (Southampton, UK) have entered into an agreement to develop iQur’s tandem core vaccine for hepatitis A and B.
Eden Biodesign Ltd. (Liverpool, UK) and iQur Ltd. (Southampton, UK) have entered into an agreement to develop iQur’s tandem core vaccine for hepatitis A and B. Eden will develop a unique biomanufacturing process to achieve optimal product quality in line with cost of goods parameters before proceeding with clinical cGMP manufacture. The project to develop the vaccine also will involve a consortium of collaborators, including Arecor (Bedfordshire, UK), who will apply its proprietary protein stabilization technology, and Mologic (Bedford, UK), who will develop its novel yeast expression systems.
Research conducted by iQur has suggested that its novel vaccine platform, based on the HBV core protein, can carry antigens specific for both hepatitis A and B simultaneously. Because the construct is highly immunogenic, it should dramatically increase vaccine efficiency and reduce the current need for booster vaccinations, said Eden in a press release. The vaccine platform will also serve as a proof-of-concept for other combination vaccines.
Eden release (PDF)
The Solution Lies with SOLBIOTE™: Achieving Sustainability, a Growing Focus in Biopharma
October 28th 2024The nexus between biopharmaceuticals and sustainability is seemingly far apart, however, it is increasingly recognized as an inevitable challenge. It is encouraged to take a sustainable approach to reducing the environmental impact of the production and supply of medicines while improving people's health; delivering the well-being of people and the planet. Yosuke Shimojo (Technical Value Support Section Manager, Nagase Viita) will unveil how SOLBIOTE™, a portfolio of injectable-grade saccharide excipients, would be a key for the biopharmaceutical development and achieving sustainability for a better future of the industry.
